Reactivation of Oxidized Soluble Guanylate Cyclase as a Novel Treatment Strategy to Slow Progression of Calcific Aortic Valve Stenosis: Preclinical and Randomized Clinical Trials to Assess Safety and Efficacy
Circulation · 2025
DOI: 10.1161/circulationaha.123.066523 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Circulation, 2025. Verfasst von Bin Zhang und 23 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Surgery (B.Z., C.M.R., M.A.H., H.Z., G.C.-V., J.S., B.D., J.D.M.), Mayo Clinic, Rochester, MN. Hauptthemen laut MEDLINE: Aortic Valve Stenosis, Aortic Valve, Calcinosis, Soluble Guanylyl Cyclase. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 64 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Pharmacological treatments for fibrocalcific aortic valve stenosis (FCAVS) have been elusive for >50 years. Here, we tested the hypothesis that reactivation of oxidized sGC (soluble guanylate cyclase), the primary receptor for nitric oxide, with ataciguat is a safe and efficacious strategy to slow progression of FCAVS. METHODS: We used quantitative real-time reverse transcription polymerase chain reaction, Western blotting, and immunohistochemistry to characterize sGC signaling and the biological effects of ataciguat on signaling cascades related to nitric oxide, calcification, and fibrosis in excised human aortic valve tissue, aortic valve interstitial cells, and mouse aortic valves. We then conducted randomized, placebo-controlled phase I (14-day safety/tolerance) and phase II (6-month efficacy) trials in patients with moderate aortic valve stenosis. RESULTS: In excised human tissue, we found robust losses in sGC signaling despite upregulation of sGC subunits. In vitro, ataciguat increased sGC signaling and reduced BMP2 (bone morphogenetic protein 2) signaling in aortic valve interstitial cells. In mice with established FCAVS, treatment with ataciguat attenuated BMP signaling and slowed progression of valve calcification and dysfunction. In a phase I, randomized, placebo-controlled trial, treatment with ataciguat for 2 weeks was safe and well tolerated in patients with moderate FCAVS ( https://www.clinicaltrials.gov ; Unique identifier: NCT02049203). In a separate phase II, randomized, placebo-controlled trial, treatment with ataciguat for 6 months slowed the progression of aortic valve calcification and tended to slow the progression of valvular and ventricular dysfunction in patients with moderate FCAVS ( https://www.clinicaltrials.gov ; Unique identifier: NCT02481258). CONCLUSIONS: Collectively, this study highlights the therapeutic potential of the targeted restoration of the diseased/inactive form of sGC for treatment of FCAVS. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02049203. URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02481258.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departments of Surgery (B.Z., C.M.R., M.A.H., H.Z., G.C.-V., J.S., B.D., J.D.M.), Mayo Clinic, Rochester, MN.
- Cardiovascular Diseases (M.E.-S., H.I.M., R.H., S.P., V.T.N., Z.Y.), Mayo Clinic, Rochester, MN.
- Cardiovascular Surgery (H.V.S., B.D., J.D.M.), Mayo Clinic, Rochester, MN.
- Pharmacy (A.B.), Mayo Clinic, Rochester, MN.
- Anesthesiology (S.R., M.J.J.), Mayo Clinic, Rochester, MN.
- Quantitative Health Sciences (W.K.K.), Mayo Clinic, Rochester, MN.
ORCID-Profile: Maurice Enriquez-Sarano, Hartzell V Schaff, Hector I Michelena, Michael A Hagler, Sushant Ranadive, Michael J Joyner, Sorin Pislaru, Vuyisile T Nkomo, Philip A Araoz, Gurpreet Singh, Michael A Walters, Jon Hawkinson, Kevin Y Cunningham, Jaeyun Sung, Zi Ye
Zitieren
APA
Zhang, B., Enriquez-Sarano, M., Schaff, H. V., Michelena, H. I., Roos, C. M., Hagler, M. A., Zhang, H., Casaclang-Verzosa, G., Huang, R., Bartoo, A., Ranadive, S., Joyner, M. J., Pislaru, S., Nkomo, V. T., Kremers, W. K., Araoz, P. A., Singh, G., Walters, M. A., Hawkinson, J., …, & Miller, J. D. (2025). Reactivation of Oxidized Soluble Guanylate Cyclase as a Novel Treatment Strategy to Slow Progression of Calcific Aortic Valve Stenosis: Preclinical and Randomized Clinical Trials to Assess Safety and Efficacy. Circulation. https://doi.org/10.1161/circulationaha.123.066523
Vancouver
Zhang B, Enriquez-Sarano M, Schaff HV, Michelena HI, Roos CM, Hagler MA, et al. Reactivation of Oxidized Soluble Guanylate Cyclase as a Novel Treatment Strategy to Slow Progression of Calcific Aortic Valve Stenosis: Preclinical and Randomized Clinical Trials to Assess Safety and Efficacy. Circulation. 2025. doi:10.1161/circulationaha.123.066523
BibTeX
@article{Zhang2025,
author = {Zhang, Bin and Enriquez-Sarano, Maurice and Schaff, Hartzell V and Michelena, Hector I and Roos, Carolyn M and Hagler, Michael A and Zhang, Heyu and Casaclang-Verzosa, Grace and Huang, Runqing and Bartoo, Anna and Ranadive, Sushant and Joyner, Michael J and Pislaru, Sorin and Nkomo, Vuyisile T and Kremers, Walter K and Araoz, Philip A and Singh, Gurpreet and Walters, Michael A and Hawkinson, Jon and Cunningham, Kevin Y and Sung, Jaeyun and Dunagan, Brandon and Ye, Zi and Miller, Jordan D},
title = {Reactivation of Oxidized Soluble Guanylate Cyclase as a Novel Treatment Strategy to Slow Progression of Calcific Aortic Valve Stenosis: Preclinical and Randomized Clinical Trials to Assess Safety and Efficacy},
journal = {Circulation},
year = {2025},
doi = {10.1161/circulationaha.123.066523}
}
EUVIMED